1-7 of 7
Karen Small
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Paolo Ghia, Lydia Scarfò, Susan Perez, Kumudu Pathiraja, Martha Derosier, Karen Small, Christine McCrary Sisk, Nigel Patton
Journal: Blood
Blood (2017) 129 (13): 1876–1878.
https://doi.org/10.1182/blood-2016-10-748210
Published: 2017
Includes: Supplemental data
Journal Articles

A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, MD PhD, Lydia Scarfo, Kumudu Pathiraja, Martha Derosier, Karen Small, Nigel Patton
Journal: Blood
Blood (2015) 126 (23): 4171.
https://doi.org/10.1182/blood.V126.23.4171.4171
Published: 2015
Journal Articles

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Joseph M. M. Flynn, DO, MPH, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, MPH, Amy J. Johnson, PhD, Kami Maddocks, MD, Elizabeth Wiley, Karen Small, BSN, Eun Kyung Im, MD, Michael R. Grever, MD, Rajat Bannerji, MD, PhD, John C. Byrd, MD, Honghong Zhou, PhD
Journal: Blood
Blood (2013) 122 (21): 871.
https://doi.org/10.1182/blood.V122.21.871.871
Published: 2013
Journal Articles

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

Ivana Gojo, MD, Alison Walker, MD, Maureen Cooper, MD, Eric J Feldman, MD, Swaminathan Padmanabhan, MBBS, MS, Maria R Baer, MD, Jennifer Poon, PharmD, Karen Small, BSN, Da Zhang, MS, Mariola Sadowska, PhD, Rajat Bannerji, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3287.
https://doi.org/10.1182/blood.V116.21.3287.3287
Published: 2010
Journal Articles

Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients

Robert A Baiocchi, MD, PhD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Kristie A. Blum, MD, Craig C. Hofmeister, MD, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PHD, John C. Byrd, MD
Journal: Blood
Blood (2010) 116 (21): 3966.
https://doi.org/10.1182/blood.V116.21.3966.3966
Published: 2010
Journal Articles

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Kristie A. Blum, MD, Amy J. Johnson, PhD, Josh Hessler, Elizabeth Wiley, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PhD, John C. Byrd, MD
Journal: Blood
Blood (2010) 116 (21): 1396.
https://doi.org/10.1182/blood.V116.21.1396.1396
Published: 2010
Journal Articles

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Joseph M. Flynn, DO, MPH, FACP, Amy J. Johnson, PhD, Leslie Andritsos, MD, Kristie A. Blum, MD, Jeffrey A. Jones, MD, MPH, Elizabeth A. Wiley, Weihong Hu, Joshua Hessler, Lisa L. Smith, David M. Lucas, PhD, Karen Small, Paul Statkevich, Michael R. Grever, MD, Rajat Bannerji, MD, PhD, John C. Byrd, MD
Journal: Blood
Blood (2009) 114 (22): 886.
https://doi.org/10.1182/blood.V114.22.886.886
Published: 2009